[Cost-benefit analysis of conservative therapy of gastritis and peptic ulcer].
Schütz
E
E
Stolte
M
M
D000041:Absenteeism; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use; D001729:Bismuth / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D005756:Gastritis / Q000188:drug therapy / Q000191:economics*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000191:economics*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001729:Bismuth
Zur Kosten-Nutzen-Analyse der konservativen Therapie der Gastritis und des Ulkusleidens.